BEUDAMED
    12 results · 20ms · Sources: EU EUDAMED, US FDA

    Get notified when this changes

    We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.
    Filters Regulation: Us FDA ×

    MUMPS IGG TEST

    FDA 510(k)
    FDA Class 1 ·Microbiology

    Gelsoft™ Cardiovascular Patch

    FDA UDI
    VASCUTEK LTD·05037881010694·Gelsoft Gelatin Impregnated Knitted Cardiovascu...

    De Soutter Medical

    FDA UDI
    DE SOUTTER MEDICAL LIMITED·05051471149816·K-WIRE - DOUBLE TROCAR FULLY THREADED 1.2mm DIA...

    C-STEM

    FDA UDI
    DEPUY INTERNATIONAL LTD·10603295235613·C-STEM NECK SEGMENT SIZE 4 STD

    ENDOCAM Flex HD Camera System 5521

    FDA 510(k)
    FDA Class 2 ·Gastroenterology, Urology

    MASIMO SET RADICAL 7 PULSE CO-OXIMETER

    FDA 510(k)
    FDA Class 2 ·Cardiovascular

    BEHRING FIBRINTIMER A

    FDA Adverse Event
    Injury ·BEHRING DIAGNOSTIC, INC.·Product code GKT·July 1, 1997

    UNKNOWN T72 TIBIAL INSERT TRIAL

    FDA Adverse Event
    Malfunction ·STRYKER ORTHOPAEDICS MAHWAH·Product code JWH·December 21, 2010

    PINNACLE MTL INS NEUT40IDX60OD

    FDA Adverse Event
    Injury ·DEPUY ORTHOPAEDICS INC US·Product code KWA·February 14, 2013

    MECHANICAL (MANUAL) WHEELCHAIR

    FDA Adverse Event
    Malfunction ·INVAMEX·Product code IOR·July 28, 2014

    FLEXOR PARALLEL URETERAL ACCESS SHEATH AND DILATORS

    FDA Adverse Event
    Injury ·COOK INC·Product code EZN·May 21, 2019

    Anthem Model Numbers: PM3210, PM3212; Allure/Relieve Model Numbers: PM3222, PM3242, PM3262, PM3542, PM3224, PM3244 Implantation of a single-chamber pulse generator, dual-chamber pulse generator, or CRT-P is indicated in one or more of the following permanent conditions: Syncope, Presyncope, Fatigue, Disorientation, Or any combination of those symptoms. Implantation of a CRT-P is indicated for: Maintaining synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic atrial fibrillation and have NYHA Class II or III heart failure. The reduction of the symptoms of moderate to severe heart failure (NYHA Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction d35% and a prolonged QRS duration

    FDA Enforcement
    Class II ·Terminated·St Jude Medical Inc.·October 25, 2017